Good clinical practice and the use of hypofractionation radiation schedules as weapons to reduce the risk of COVID-19 infections in radiation oncology unit: A mono-institutional experience

BACKGROUND: After coronavirus disease outbreak emerged in 2019, radiotherapy departments had to adapt quickly their health system and establish new organizations and priorities. The purpose of this work is to report our experience in dealing with COVID-19 emergency, how we have reorganized our clinical activity, changed our priorities, and stressed the use of hypofractionation in the treatment of oncological diseases. MATERIALS AND METHODS: The patients' circuit of first medical examinations and follow-up was reorganized; a more extensive use of hypofractionated schedules was applied; a daily triage of the patients and staff, use of personal protective equipment, hand washing, environment sanitization, social distancing and limitations for the patients' caregivers in the department, unless absolutely essential, were performed; patients with suspected or confirmed COVID-19 were treated at the end of the day. In addition, the total number of radiotherapy treatment courses, patients and sessions, in the period from February 15 to April 30, 2020, comparing the same time period in 2018 were retrospectively investigated. In particular, changes in hypofractionated schedules adopted for the treatment of breast and prostate cancer and palliative bone metastasis were analyzed. RESULTS: Between February 15, and April 30, 2020, an increased number of treatments was carried out: Patients treated were overall 299 compared to 284 of the same period of 2018. Stressing the use of hypofractionation, 2036 RT sessions were performed, with a mean number of fractions per course of 6.8, compared to 3566 and 12.6, respectively, in 2018. For breast cancer, the schedule in 18 fractions has been abandoned and treatment course of 13 fractions has been introduced; a 27% reduction in the use of 40.5 Gy in 15 fractions, (67 treatments in 2018–49 in 2020) was reported. An increase of 13% of stereotactic body radiation therapy for prostate cancer was showed. The use of the 20 Gy in 4 or 5 sessions for the treatment of symptomatic bone metastasis decreased of 17.5% in favor of 8 Gy-single fraction. Three patients results COVID-19 positive swab: 1 during, 2 after treatment. Only one staff member developed an asymptomatic infection. CONCLUSIONS: The careful application of triage, anti-contagion and protective measures, a more extensive use of hypofractionation allowed us to maintain an effective and continuous RT service with no delayed/deferred treatment as evidenced by the very low number of patients developing COVID-19 infection during or in the short period after radiotherapy. Our experience has shown how the reorganization of the ward priority, the identification of risk factors with the relative containment measures can guarantee the care of oncological patients, who are potentially at greater risk of contracting the infection.

[1]  L. Beckman,et al.  Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer (HYPO-RT-PC): patient-reported quality-of-life outcomes of a randomised, controlled, non-inferiority, phase 3 trial. , 2021, The Lancet. Oncology.

[2]  V. Borzillo,et al.  COVID-19 and radiotherapy: potential new strategies for patients management with hypofractionation and telemedicine. , 2020, European review for medical and pharmacological sciences.

[3]  S. Evans,et al.  A multi-institutional assessment of COVID-19-related risk in radiation oncology , 2020, Radiotherapy and Oncology.

[4]  G. Sanguineti,et al.  Head and neck radiotherapy amid the COVID-19 pandemic: practice recommendations of the Italian Association of Radiotherapy and Clinical Oncology (AIRO) , 2020, Medical Oncology.

[5]  Y. Belkacemi,et al.  Radiation Therapy Department Reorganization during the Coronavirus Disease 2019 (COVID-19) Outbreak: Keys to Securing Staff and Patients During the First Weeks of the Crisis and Impact on Radiation Therapy Practice from a Single Institution Experience , 2020, Advances in Radiation Oncology.

[6]  Y. Belkacemi,et al.  Regional Lymph Node Irradiation in Breast Cancer May Worsen Lung Damage in Coronavirus Disease 2019 Positive Patients , 2020, Advances in Radiation Oncology.

[7]  R. Corvò,et al.  COVID-19 outbreak and cancer radiotherapy disruption in Italy: Survey endorsed by the Italian Association of Radiotherapy and Clinical Oncology (AIRO)☆ , 2020, Radiotherapy and Oncology.

[8]  A. Kishan,et al.  Prostate Cancer Radiation Therapy Recommendations in Response to COVID-19 , 2020, Advances in Radiation Oncology.

[9]  R. Jagsi,et al.  International Guidelines on Radiation Therapy for Breast Cancer During the COVID-19 Pandemic , 2020, Clinical Oncology.

[10]  R. Corvò,et al.  Letter from Italy: First practical indications for radiation therapy departments during COVID-19 outbreak , 2020, International Journal of Radiation Oncology*Biology*Physics.

[11]  C. Simone,et al.  Stereotactic body radiation therapy for prostate cancer: systematic review and meta-analysis of prospective trials , 2019, Oncotarget.

[12]  L. Beckman,et al.  Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial , 2019, The Lancet.

[13]  A. Kishan,et al.  Stereotactic Body Radiation Therapy for Localized Prostate Cancer: A Systematic Review and Meta-Analysis of Over 6,000 Patients Treated On Prospective Studies. , 2019, International journal of radiation oncology, biology, physics.

[14]  M. Scorsetti,et al.  Postmastectomy radiation therapy using VMAT technique for breast cancer patients with expander reconstruction , 2019, Medical Oncology.

[15]  K. Hoffman,et al.  Hypofractionated Radiation Therapy for Localized Prostate Cancer: An ASTRO, ASCO, and AUA Evidence-Based Guideline. , 2018, The Journal of urology.

[16]  P. Hoskin,et al.  Efficacy of single fraction conventional radiation therapy for painful uncomplicated bone metastases: a systematic review and meta-analysis. , 2017, Annals of palliative medicine.

[17]  D. Low,et al.  Randomized Phase III Noninferiority Study Comparing Two Radiotherapy Fractionation Schedules in Patients With Low-Risk Prostate Cancer. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  Annie Gao,et al.  Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial , 2016, The Lancet. Oncology.

[19]  B. Heijmen,et al.  Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open-label, phase 3 trial. , 2016, The Lancet. Oncology.

[20]  C. Magnani,et al.  Hypofractionated Radiation Therapy for Breast Cancer: Long-Term Results in a Series of 85 Patients , 2016, Tumori.

[21]  Anthony Fyles,et al.  Long-term results of hypofractionated radiation therapy for breast cancer. , 2010, The New England journal of medicine.

[22]  J R Yarnold,et al.  The UK Standardisation of Breast Radiotherapy (START) Trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial , 2008, The Lancet.

[23]  K. Wallner,et al.  Severity categories of the International Prostate Symptom Score before, and urinary morbidity after, permanent prostate brachytherapy , 2006, BJU international.

[24]  John E Tomaszewski,et al.  Biochemical outcome after radical prostatectomy or external beam radiation therapy for patients with clinically localized prostate carcinoma in the prostate specific antigen era , 2002, Cancer.

[25]  A. Renshaw,et al.  Biochemical Outcome after radical prostatectomy, external beam Radiation Therapy, or interstitial Radiation therapy for clinically localized prostate cancer , 1998 .

[26]  E. van Limbergen,et al.  Prognostic Factors for Local Control in Breast Cancer After Long-term Follow-up in the EORTC Boost vs No Boost Trial: A Randomized Clinical Trial , 2017, JAMA oncology.

[27]  R. Stoyanova,et al.  Randomized trial of hypofractionated external-beam radiotherapy for prostate cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.